Topic: nonalcoholic steatohepatitis (NASH)
In a pivotal phase 3 study, Intercept Pharmaceuticals' obeticholic acid improved liver fibrosis without any worsening of NASH after 18 months.
The ASK1 inhibitor was no better than placebo at improving fibrosis, wiping out hopes that selonsertib would spearhead Gilead’s push into a new field.
Gilead’s VP of clinical research, Erin Quirk, is joining the NASH and cancer-focused Terns Pharmaceuticals as its new chief medical officer.
Shares in the nanocap biotech shot up more than 100% in premarket trading before falling away somewhat as people dug deeper into the data.
As the dust settles on another chaotic week, biotechs are not standing still.
The agreement gives Merck control of a drug designed to reduce liver fat content by selectively activating FGFR1c.
Gilead and Scholar Rock are joining forces on new drugs for fibrotic diseases that inhibit the activation of transforming growth factor beta.
Akero will push a nonalcoholic steatohepatitis treatment licensed from Amgen through phase 2, and expand its pipeline.
The setback wiped 55% off Conatus’ stock in premarket trading as investors digested the implications of a second midphase failure in eight months.